AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18022303 — intervention group
Group type: EXPERIMENTAL
Intervention: Right substantia nigra (SN) volume
Number of subjects: 35
Study 18022303 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study 18022303 — intervention group
Group type: EXPERIMENTAL
Intervention: Right motor deficits (RPD)
Number of subjects: 35
Study 17072957 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal splenorenal shunt (DSRS)
Number of subjects: 80
Study 17072957 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sclerotherapy (ES)
Number of subjects: 80
Study 12013322 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapies for stroke risk factors
Number of subjects: 16148
Study 12013322 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 16148
Study 12013322 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercholesterolaemia
Number of subjects: 16148
Study 12013322 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 16148
Study 12013322 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular agents
Number of subjects: 16148
Study 12013322 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet agents
Number of subjects: 16148
Study 12013322 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 16148
Study 9864106 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion under the right hemidiaphragm (Group B)
Number of subjects: 300
Study 9864106 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 1.5 mg/kg infusion under the right hemidiaphragm (Group C)
Number of subjects: 300
Study 9864106 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine infusion with subhepatic drain (Group D)
Number of subjects: 300
Study 9864106 — intervention group
Group type: COMPARATOR
Intervention: Normal saline plus bupivacaine infusion (Group E)
Number of subjects: 300
Study 9864106 — intervention group
Group type: COMPARATOR
Intervention: Normal saline plus bupivacaine with subhepatic drain (Group F)
Number of subjects: 300
Study 8560535 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 731
Study 8560535 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole
Number of subjects: 731
Study 1983610 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 744
Study 1983610 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical therapy
Number of subjects: 744
Study 1247378 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise plus biofeedback training
Number of subjects: 20
Study 1247378 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical exercise
Number of subjects: 20
Study 7016242 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral subcutaneous sphincterotomy under general anaesthesia (n = 37)
Number of subjects: 71
Study 7016242 — intervention group
Group type: COMPARATOR
Intervention: Lateral subcutaneous sphincterotomy under local anaesthesia (n = 34)
Number of subjects: 71
Study 31613408 — intervention group
Group type: EXPERIMENTAL
Intervention: Myelomeningocele sac presence
Number of subjects: 404
Study 31613408 — intervention group
Group type: EXPERIMENTAL
Intervention: Myelomeningocele sac size
Number of subjects: 404
Study 31613408 — intervention group
Group type: COMPARATOR
Intervention: Myelomeningocele vs Myeloschisis
Number of subjects: 404
Study 31613408 — intervention group
Group type: COMPARATOR
Intervention: Myelomeningocele with hindbrain herniation
Number of subjects: 404
Study 28954570 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution-Focused Brief Couple Therapy (SFBCT)
Number of subjects: 100
Study 28954570 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 100
Study 27007594 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate mouthwash (every 6 hours)
Number of subjects: 0
Study 27007594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25102328 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX) 25 mg/d for 8 weeks
Number of subjects: 24
Study 25102328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 21925716 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD0837 (150, 250 or 350 mg)
Number of subjects: 65
Study 21925716 — intervention group
Group type: EXPERIMENTAL
Intervention: ximelagatran (36 mg twice daily)
Number of subjects: 65
Study 21925716 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonist (VKA) titrated to INR of 2-3
Number of subjects: 65
Study 21925716 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy elderly subjects)
Number of subjects: 65
Study 20806988 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine XR (1-4 mg/day)
Number of subjects: 217
Study 20806988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 17851996 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional counseling intervention (NC arm)
Number of subjects: 50
Study 17851996 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention with oxandrolone (OX arm)
Number of subjects: 50
Study 17851996 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention with progressive resistance training (PRT arm)
Number of subjects: 50
Study 15758667 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 268
Study 15758667 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous smokers
Number of subjects: 268
Study 12137879 — intervention group
Group type: EXPERIMENTAL
Intervention: Zona-free blastocyst transfer
Number of subjects: 240
Study 12137879 — intervention group
Group type: COMPARATOR
Intervention: Zona-intact blastocyst transfer
Number of subjects: 240
Study 10098789 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-use water disinfection, safe storage, and community education
Number of subjects: 127
Study 7762461 — intervention group
Group type: EXPERIMENTAL
Intervention: Home therapy
Number of subjects: 0
Study 7762461 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based care
Number of subjects: 0
Study 2180271 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 100 mg/m2 alone (group I)
Number of subjects: 53
Study 2180271 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2 and oral disulfiram 2000 mg/m2 (group II)
Number of subjects: 53
Study 453982 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathoracic intercostal block with bupivacaine
Number of subjects: 0
Study 31069935 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster aspart (0.3 U/kg)
Number of subjects: 61
Study 31069935 — intervention group
Group type: COMPARATOR
Intervention: Insulin aspart (IAsp) (0.3 U/kg)
Number of subjects: 61
Study 29250529 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD‐GRIP intervention (nurse-led illness perception intervention)
Number of subjects: 204
Study 29250529 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 204
Study 26502953 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhodiola rosea L (2 × 200 mg dose Vitano®, 1 tablet taken before breakfast and 1 tablet before lunch)
Number of subjects: 80
Study 26502953 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no treatment)
Number of subjects: 80
Study 25603659 — intervention group
Group type: EXPERIMENTAL
Intervention: Off pump CABG (group-B)
Number of subjects: 200
Study 25603659 — intervention group
Group type: COMPARATOR
Intervention: On pump CABG (group-A)
Number of subjects: 200
Study 21094048 — intervention group
Group type: EXPERIMENTAL
Intervention: Skill focused instruction
Number of subjects: 18
Study 21094048 — intervention group
Group type: COMPARATOR
Intervention: No instruction
Number of subjects: 18
Study 20028190 — intervention group
Group type: EXPERIMENTAL
Intervention: Online, video-based education
Number of subjects: 78
Study 20028190 — intervention group
Group type: COMPARATOR
Intervention: Written educational material (pamphlet)
Number of subjects: 78
Study 17310505 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric banding surgery
Number of subjects: 50
Study 17310505 — intervention group
Group type: COMPARATOR
Intervention: Normal weight control group
Number of subjects: 50
Study 15380963 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive treatment (angiography and intervention within 24 hours of thrombolysis)
Number of subjects: 500
Study 15380963 — intervention group
Group type: COMPARATOR
Intervention: Conservative approach (ischaemia-guided)
Number of subjects: 500
Study 12511208 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyad Intervention (DI)
Number of subjects: 0
Study 12511208 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver Intervention (CI)
Number of subjects: 0
Study 12511208 — intervention group
Group type: COMPARATOR
Intervention: Wait List Control (WLC)
Number of subjects: 0
Study 12511208 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyad Intervention (DI) for care-recipients
Number of subjects: 0
Study 12511208 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver Intervention (CI) for care-recipients
Number of subjects: 0
Study 12511208 — intervention group
Group type: COMPARATOR
Intervention: Wait List Control (WLC) for care-recipients
Number of subjects: 0
Study 9694317 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training at ventilatory threshold (Vth), walking/jogging sessions twice a week, duration increased from 30 min to 1 h over 3 months
Number of subjects: 22
Study 8589465 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% low molecular weight dextran at 25 mL/hr
Number of subjects: 19
Study 8589465 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 19
Study 2760258 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin (NOR) 800 mg/d
Number of subjects: 8
Study 2760258 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (C) 1 g/d
Number of subjects: 8
Study 2760258 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalidixic acid (NAL) 2 g/d
Number of subjects: 8
Study 2760258 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 8
Study 62613 — intervention group
Group type: EXPERIMENTAL
Intervention: BACON plus BCG
Number of subjects: 34
Study 62613 — intervention group
Group type: COMPARATOR
Intervention: BACON
Number of subjects: 34
Study 29796671 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosodium glutamate (MSG) supplemented vegetable broth (3.8 g MSG daily for 4 weeks)
Number of subjects: 58
Study 29796671 — intervention group
Group type: COMPARATOR
Intervention: Sodium-matched broth without MSG (control)
Number of subjects: 58
Study 28370134 — intervention group
Group type: EXPERIMENTAL
Intervention: FLEXITHERALIGHT protocol (fractionated irradiation with 12.3 mW/cm2 after 30 minutes incubation time)
Number of subjects: 0
Study 28370134 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol (continuous irradiation with 75 mW/cm2 after 3 hours incubation time)
Number of subjects: 0
Study 26180109 — intervention group
Group type: EXPERIMENTAL
Intervention: Technosphere insulin (TI)
Number of subjects: 345
Study 26180109 — intervention group
Group type: COMPARATOR
Intervention: Insulin aspart (C)
Number of subjects: 345
Study 22181827 — intervention group
Group type: EXPERIMENTAL
Intervention: QS ruby laser, aggressive treatment (Group 1)
Number of subjects: 193
Study 22181827 — intervention group
Group type: EXPERIMENTAL
Intervention: QS ruby laser, mild treatment (Group 2)
Number of subjects: 193
Study 22181827 — intervention group
Group type: EXPERIMENTAL
Intervention: QS frequency doubled Nd:YAG laser, aggressive treatment (Group 3)
Number of subjects: 193
Study 22181827 — intervention group
Group type: EXPERIMENTAL
Intervention: QS frequency doubled Nd:YAG laser, mild treatment (Group 4)
Number of subjects: 193
Study 20962614 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon‐α administration during structured treatment interruptions (STIs)
Number of subjects: 168
Study 20962614 — intervention group
Group type: COMPARATOR
Intervention: Control group (without α‐interferon)
Number of subjects: 168
Study 18788026 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional faces (sad, happy, fearful)
Number of subjects: 21
Study 17459295 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diflucortolone valerate 0.001 percent and oral cetirizine hydrochloride (Group A)
Number of subjects: 50
Study 17459295 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin in addition to topical diflucortolone valerate and oral cetirizine hydrochloride (Group B)
Number of subjects: 50
Study 17459295 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone or intralesional triamcinolone acetonide (for severe cases)
Number of subjects: 50
Study 12729776 — intervention group
Group type: EXPERIMENTAL
Intervention: Prelaminated fasciomucosal flaps
Number of subjects: 32
Study 12729776 — intervention group
Group type: COMPARATOR
Intervention: Non-prelaminated fasciocutaneous flaps
Number of subjects: 32
Study 10937329 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8927677 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (7 mg/day for nonsmokers and 21 mg/day for smokers)
Number of subjects: 17
Study 8927677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 1642023 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and/or oral antidiabetics
Number of subjects: 751
Study 1642023 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 751
Study 6403965 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ)
Number of subjects: 0
Study 6403965 — intervention group
Group type: EXPERIMENTAL
Intervention: Promazine
Number of subjects: 0
Study 6403965 — intervention group
Group type: COMPARATOR
Intervention: Control experiments
Number of subjects: 0
Study 31462460 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure with stroke
Number of subjects: 1023
Study 29364357 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention providing normative feedback on alcohol consumption, risks, and tips to reduce damage.
Number of subjects: 465
Study 29364357 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 465
Study 28219056 — intervention group
Group type: EXPERIMENTAL
Intervention: 927 ppm F/5% CSPS
Number of subjects: 77
Study 28219056 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 ppm F/5% CSPS
Number of subjects: 77
Study 28219056 — intervention group
Group type: COMPARATOR
Intervention: 927 ppm F/0% CSPS
Number of subjects: 77
Study 28219056 — intervention group
Group type: COMPARATOR
Intervention: 0 ppm F/0% CSPS
Number of subjects: 77
Study 26156248 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal Occult Blood Testing (FOBT)
Number of subjects: 198
Study 26156248 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical Colonoscopy (OC)
Number of subjects: 198
Study 26156248 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Colonoscopy (VC)
Number of subjects: 198
Study 23526980 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper quartile of baseline WBC counts
Number of subjects: 1637
Study 23526980 — intervention group
Group type: EXPERIMENTAL
Intervention: Top quartile of leukocyte count
Number of subjects: 1637
Study 23526980 — intervention group
Group type: EXPERIMENTAL
Intervention: Top quartile of neutrophil count
Number of subjects: 1637
Study 23526980 — intervention group
Group type: EXPERIMENTAL
Intervention: Top quartile of lymphocyte count
Number of subjects: 1637
Study 23526980 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in total WBC during follow-up
Number of subjects: 1637
Study 23526980 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte and neutrophil count
Number of subjects: 1637
Study 23526980 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphocyte counts
Number of subjects: 1637
Study 21173348 — intervention group
Group type: EXPERIMENTAL
Intervention: Final Kissing Balloon Dilatation (FKBD)
Number of subjects: 477
Study 21173348 — intervention group
Group type: COMPARATOR
Intervention: No Final Kissing Balloon Dilatation (no FKBD)
Number of subjects: 477
Study 18489412 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother-baby intervention (8-10 home visits)
Number of subjects: 71
Study 18489412 — intervention group
Group type: COMPARATOR
Intervention: Parenting support by telephone (control group)
Number of subjects: 71
Study 17137597 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based respiratory safety training with text, pictures, and audio narration
Number of subjects: 0
Study 17137597 — intervention group
Group type: COMPARATOR
Intervention: Computer-based respiratory safety training (general)
Number of subjects: 0
Study 14624375 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN alone or combined with ribavirin (RBV)
Number of subjects: 10
Study 14624375 — intervention group
Group type: COMPARATOR
Intervention: Standard IFN plus RBV
Number of subjects: 10
Study 14624375 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN or IFN
Number of subjects: 10
Study 14624375 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV treatment
Number of subjects: 10
Study 11113401 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (combined with cholestyramine and/or nicotinic acid) to achieve LDL cholesterol levels of < or =130 mg/dl (group A)
Number of subjects: 126
Study 11113401 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B) with antilipidemic therapy determined by family physicians
Number of subjects: 126
Study 11113401 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin-based therapy (group A)
Number of subjects: 126
Study 11113401 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 126
Study 8702032 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine regimen
Number of subjects: 4127
Study 8702032 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine regimen
Number of subjects: 4127
Study 8702032 — intervention group
Group type: EXPERIMENTAL
Intervention: No prophylaxis before first antenatal clinic visit
Number of subjects: 4127
Study 8702032 — intervention group
Group type: EXPERIMENTAL
Intervention: High transmission season
Number of subjects: 4127
Study 8702032 — intervention group
Group type: EXPERIMENTAL
Intervention: Young age (< 20 years)
Number of subjects: 4127
Study 8702032 — intervention group
Group type: EXPERIMENTAL
Intervention: Low hematocrit
Number of subjects: 4127
Study 8702032 — intervention group
Group type: EXPERIMENTAL
Intervention: Short stature
Number of subjects: 4127
Study 8702032 — intervention group
Group type: EXPERIMENTAL
Intervention: Second trimester (compared with third trimester)
Number of subjects: 4127
Study 7703926 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of AmBisome
Number of subjects: 200
Study 7703926 — intervention group
Group type: COMPARATOR
Intervention: Later use of AmBisome
Number of subjects: 200
Study 3297472 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 360 mg
Number of subjects: 8
Study 3297472 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine >90 mg
Number of subjects: 8
Study 3297472 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (dose-related)
Number of subjects: 8
Study 3297472 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (not dose-related)
Number of subjects: 8
Study 3297472 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 8
Study 31327670 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized 15% xylitol (5 ml) twice a day for 14 days
Number of subjects: 60
Study 31327670 — intervention group
Group type: COMPARATOR
Intervention: Aerosolized 7% hypertonic saline (4 ml) twice a day for 14 days
Number of subjects: 60
Study 29211295 — intervention group
Group type: EXPERIMENTAL
Intervention: IROX/Bev (for TS-H tumors)
Number of subjects: 247
Study 29211295 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX/Bev (for TS-H tumors)
Number of subjects: 247
Study 29211295 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX/Bev (for TS-L tumors)
Number of subjects: 247
Study 27350298 — intervention group
Group type: EXPERIMENTAL
Intervention: STA-MCA anastomosis
Number of subjects: 30
Study 27350298 — intervention group
Group type: COMPARATOR
Intervention: Control (conservative treatment)
Number of subjects: 30
Study 25006069 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunologically castrated (IC) barrows
Number of subjects: 47
Study 23880340 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydextrose (PDX) diet
Number of subjects: 18
Study 23880340 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble maize fibre (SCF) diet
Number of subjects: 18
Study 23880340 — intervention group
Group type: COMPARATOR
Intervention: Control diet (full energetic)
Number of subjects: 18
Study 23880340 — intervention group
Group type: COMPARATOR
Intervention: Control diet (isoenergetic)
Number of subjects: 18
Study 23163143 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive protocol of integrative medicine (naomai jiejing decoction No. 1 and No. 2)
Number of subjects: 63
Study 23163143 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy and nimodipine (control group)
Number of subjects: 63
Study 20577753 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 60
Study 20577753 — intervention group
Group type: COMPARATOR
Intervention: Microdrill
Number of subjects: 60
Study 18032857 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbinafine 250 mg, one tablet twice daily for seven days every month (pulse therapy)
Number of subjects: 96
Study 18032857 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbinafine pulse therapy plus topical ciclopirox olamine 8% applied once daily at night
Number of subjects: 96
Study 18032857 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbinafine pulse therapy plus topical amorolfine hydrochloride 5% applied once weekly at night
Number of subjects: 96
Study 16151607 — intervention group
Group type: EXPERIMENTAL
Intervention: KTP 532-nm laser treatment with pulse duration (PD) varying from 0.13 to 1.71 times thermal relaxation time (Tr)
Number of subjects: 28
Study 16151607 — intervention group
Group type: EXPERIMENTAL
Intervention: KTP 532-nm laser treatment with PD near or higher than Tr
Number of subjects: 28
Study 11967748 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% with sufentanil 2 microgram/ml
Number of subjects: 40